Top Feed
ADI - ADI’s European Region Roundup for October 2025
Eli Lilly's Alzheimer's drug rejected in Europe
ADI - 35th Alzheimer Europe Conference
Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III
Harmonized prevalence estimates of dementia in Europe vary strongly with childhood education
European regulators endorse Lilly’s Alzheimer’s treatment for certain patients
Lilly calls for 'urgent improvements' in Europe to boost diagnostic testing for Alzheimer's
Anavex presents oral blarcamesine data at Alzheimer Europe Conference
Kisunla approval offers new option to treat early Alzheimer’s in Europe
Experts call for urgent action to improve Alzheimer’s diagnosis across Europe
Eli Lilly and leading Alzheimer's disease experts have called...
ADI - ADI’s European Region Roundup for October 2025
From Switzerland to Italy, ADI has taken part in key engagements on the European continent that convened industry leaders, clinicians,...
Eli Lilly's Alzheimer's drug rejected in Europe
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not...
ADI - 35th Alzheimer Europe Conference
The 35th Alzheimer Europe...
Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia...
Harmonized prevalence estimates of dementia in Europe vary strongly with childhood education
These new data exhibit much higher prevalence rates of dementia in the Mediterranean and Southeastern European countries and a much larger variation of...
European regulators endorse Lilly’s Alzheimer’s treatment for certain patients
Lilly's next challenge will be getting European countries to reimburse Kisunla. Some cost-effectiveness watchdogs have taken issue with the...
Lilly calls for 'urgent improvements' in Europe to boost diagnostic testing for Alzheimer's
Eli Lilly is calling on European countries to make...
Anavex presents oral blarcamesine data at Alzheimer Europe Conference
(NASDAQ:AVXL), a biotech company with a market capitalization of $818 million that has delivered an impressive 86% return over the past year,...
Kisunla approval offers new option to treat early Alzheimer’s in Europe
European approval of Kisunla comes just over a year after it was approved in the U.S. for a similar indication. It has also been authorized to...
Alzheimer Europe
@AlzheimerEurope
1755
Stats
70636
Rank
1.8K
Points
0
Videos
10
Articles
0
Reviews
0
Comments